{"id":"a3b9d306fc8a","type":"article","url":"https://hartvaat.nl/2026/09/01/cardiorenale-risicos-bij-type-1-diabetes-een-overzicht-van-de-huidige-stand-van-/","title":"Cardiorenale risico’s bij type 1-diabetes — een overzicht van de huidige stand van zaken","title_en":"Current State of Cardiorenal Disease in People with Type 1 Diabetes.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","internist"],"tags":[],"journal":"Endocrinology and metabolism clinics of North America","doi":"10.1016/j.ecl.2026.04.004","source_url":"https://doi.org/10.1016/j.ecl.2026.04.004","authors":["Stuti Fernandes","Barbara Hettinger","Lynn Ang","Rodica Pop-Busui"],"significance":3,"published":"2026-08-07","source_date":"2026-09-01","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"Individuals with type 1 diabetes (T1D) face a substantially elevated risk of cardiovascular disease, heart failure, and chronic kidney disease. While novel glucose-lowering agents have demonstrated significant cardiorenal protection in type 2 diabetes, patients with T1D have historically been excluded from most outcome trials. This review synthesizes current evidence on the high cardiorenal burden in T1D and highlights the clinical need for targeted risk management and dedicated research in this population.","created":"2026-08-01T00:49:05Z","updated":"2026-08-10T10:36:45Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Patiënten met type 1-diabetes (T1D) lopen een aanzienlijk verhoogd risico op cardiovasculaire aandoeningen, hartfalen en chronische nierziekte. Hoewel nieuwe diabetesmedicatie bij type 2-diabetes bewezen hart- en nierbescherming biedt, werden T1D-patiënten tot voor kort vrijwel uitgesloten van deze trials. Dit overzicht beschrijft de beschikbare data over de hoge cardiorenale belasting bij T1D en benadrukt de noodzaak van gerichte monitoring en toekomstig onderzoek naar preventieve strategieën in deze populatie.","abstract_original":"This article highlights the increased risk of cardiovascular and renal disease in individuals with type 1 diabetes (T1D). In recent years, the treatment landscape of type 2 diabetes has been revolutionized beyond strictly glycemic and metabolic effects by drugs, which have been shown to have additional benefits, including substantial cardiovascular and renal protection. However, until very recently, individuals with T1D were excluded from most trials that evaluated cardiovascular disease (CVD) and chronic kidney disease (CKD) risk with these agents. Here we discuss the data highlighting the high CVD, heart failure (HF), and CKD risk in T1D."}